Slide 1: Fiscal 2026 Q3 Financial Results
Fiscal 2026 Q3 Financial Results AUGU ST 2026 PROPRIETARY and CONFIDENTIAL | TWIST BIOSCIENCE
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Li
Slide 3: 14 Consecutive Quarters of Sequential Revenue Growth
14 Consecutive Quarters of Sequential Revenue Growth Revenue ($ in Millions) NGS Applications DNA Synthesis & Protein Solutions Dec $ 17.2 Mar 19.3 Jun 21.2 Sep 32.4 Dec 28.2 Mar 31.2 Jun 35.0 Sep 38.0 Dec 42.0 Mar 48.1 Jun 56.1 Sep 57.3 Dec 54.2 Mar 60.2 Jun 63.7 Sep 66.9 Dec 71.5 Mar 75.3 Jun 81.5
Slide 4: Serving Customers Across Multiple Industries
Serving Customers Across Multiple Industries Therapeutics Diagnostics Academic Industrial & Government & Applied PROPRIETARY | TWIST BIOSCIENCE | 4
Slide 5: AI Driving Durable Growth in Short, Medium, Long Term
AI Driving Durable Growth in Short, Medium, Long Term Large Traditional Dry lab Large tech Biotech pharma pharma biotech companies Conducting Model Building Discovery using Model Iterating Models (Turning the Crank) Create recurring value Generate the biological through continuous data for foundatio
Slide 6: AI Aims to Reduce Future Costs, Improve Attrition and Shrink Timelines
AI Aims to Reduce Future Costs, Improve Attrition and Shrink Timelines Molecules that survive each stage of traditional drug discovery Discovery & screening Preclinical Phase I Phase II Phase III & approval 5,000–10,000* ~250* ~5* ~2* 1* compounds screened enter preclinical first-in-human advance to
Slide 7: AI-Enabled Discovery: A Durable Growth Engine
AI-Enabled Discovery: A Durable Growth Engine Preclinical 1 Design 2 Build 3 Build 4 Test 5 Test development & AI-Generated DNA Synthesis Protein Expression Characterization Lead Candidates animal studies Sequences Millions of candidate DNA High-throughput synthesis of Expression of the proteins Ass
Slide 8: Supporting Global Health
Supporting Global Health Twist Comprehensive Viral Research Panel • Over 1M unique probes • Target 3,153 viral genomes • Background: ▪ May 15, 2026, public health officials in the Democratic Republic of Congo (DRC) announced developing outbreak of hemorrhagic fever. ▪ Outbreak went undetected for at
Slide 9: Strong Accelerating Momentum for NGS Applications
Strong Accelerating Momentum for NGS Applications Revenue growth led by diagnostic customers Escalation of commercial volumes and pre-commercial activities New opportunities • Next generation assays • Tumor-informed MRD tests • Optimized workflows using proprietary enzymes PROPRIETARY | TWIST BIOSCI
Slide 10: Inaugural Investor Day
Inaugural Investor Day Wilsonville, OR Customer presentations across multiple markets and applications including: • DSPS: enzyme engineering, siRNA drug discovery, AI-enabled discovery, academic research • NGS: MRD, exome sequencing, FlexPrep for AgBio, OEM partnership Scaling innovation with: • Ope
Slide 11: Robust and Expanding Competitive Moat
Robust and Expanding Competitive Moat Manufacturing Customer Automation Experience Existing Infrastructure Scientific Supports Continued Scale Software Innovation Customer Commercial Engagement Execution Product Development PROPRIETARY | TWIST BIOSCIENCE | 11
Slide 12: Continuing to Iterate and Improve Proprietary Platform
Continuing to Iterate ~60% and Improve Cost ($) reduction in cost Proprietary Platform 1H2023 2H2023 2024 2025 1Q2026 2Q2026 • Continuing low error rate with improved consistency 51.4 • Continue to reduce reagent cost and 31.4 29.4 23.1 ~70% Waste chemical waste 14.4 reduction (Liter) In waste • Fas
Slide 13: Complex DNA. Simple everything else.
✓ Simple, automated ordering Complex DNA. ✓ Complete transparency Simple everything else. ✓ Predictable turnaround time ✓ Reliable synthesis Complex gene synthesis from Twist ✓ Affordable pricing During early access*: >1,800 >100 12 day complex genes orders turnaround time for majority of orders *Ea
Slide 14: 3Q FY26: On Track to Adj EBITDA Breakeven in 4Q FY26
3Q FY26: On Track to Adj EBITDA Breakeven in 4Q FY26 $118.4M 52.8% Gross $(11.3)M Adj. Revenue Margin EBITDA* Beat Guidance of $114-115M ~120 basis points of Approaching Revenue Growth of sequential growth breakeven 23% YoY compared to 2Q FY26 Cash, Cash Equivalents and Short-term Investments as of
Slide 15: DNA Synthesis & Protein Solutions
DNA Synthesis & Protein Solutions 3Q FY26 Products • $56.6 million in revenue • Growth of 39% YoY and 6% sequentially • Clonal genes • Physically shipped approximately 369,000 genes • Express genes • Sequential growth for genes manufactured for data characterization • Complex genes* • Gene fragments
Slide 16: NGS Applications
NGS Applications Products 3Q FY26 • Fixed panels • $61.8 million in revenue • Custom panels • Growth of 12% YoY and 8% sequentially • Alliance panels • Twist Comprehensive Viral Research Panel enabled researchers in • Library prep kits the DRC to identify a rare strain of Ebola that evaded PCR tests
Slide 17: Revenue by Geography
Revenue by Geography $ in Millions Americas EMEA APAC Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 PROPRIETARY | TWIST BIOSCIENCE | 17
Slide 18: 3QFY26 Industry Revenue Reporting
3QFY26 Industry Revenue Reporting Industry Reporting (% change vs. 3QFY25) +49% +15% +32% -6% -1% Academic and Industry and Global supply Therapeutics Diagnostics Government applied partners $40.4M $43.8M $15.5M $5.7M $12.9M Discovery research Tools for NGS assays, Chemical and enzyme Research OEMs
Slide 19: Key Metrics: Revenue, Gross Margin, Adj EBITDA
Key Metrics: Revenue, Gross Margin, Adj EBITDA Quarterly Revenue $456 - $457 $ in Millions Annual Revenue $ in Millions $376.6 $118.4 $313.0 51% >52% 52.8% GM GM GM $245.1 $203.6 $132.2 43% 41% GM $90.1 39% GM 37% GM GM 32% GM FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 Guidance FY26 Q3
Slide 20: Adjusted EBITDA Progress Toward Break-even in 4Q FY26
Adjusted EBITDA Progress Toward Break-even in 4Q FY26 $118.4 $ in Millions $110.7 $103.7 $96.1 $99.0 $92.8 $88.7 $81.5 $84.7 $75.3 $71.5 $66.9 53.4% 52.0% 52.8% 51.3% 51.6% 48.3% 49.6% 45.1% 43.3% 40.5% 41.0% 36.6% FY23Q4 FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 FY26Q1 FY26Q2 FY26Q3 R
Slide 21: FY2026 Guidance
FY2026 Guidance* Q4 FY2026 FY2026 FY2026 REVENUE REVENUE GROSS MARGIN $123 to $124M $456 to $457M >52% Growth of 25% YoY at midpoint Growth of 21% YoY Adjusted EBITDA Breakeven Expected for Q4 FY2026** * Guidance provided as of August 3, 2026 **A reconciliation of adjusted EBITDA for the fourth quar
Slide 22: 2030: Continuing to Expand SAMs Driven by NPIs
2030: CONTINUING TO EXPAND SAMS DRIVEN BY NPIs $6B SAM and >$90B TAM $7B+ SAM* and $18B TAM NGS Applications DNA Synthesis and Protein Solutions AI-enabled Drug Discovery DNA Synthesis and Protein Solutions Nucleic Acid Therapeutics $3.6B $2.5B $2B $0.5B $1.6B $1B $0.5B $800M $500M $400M $400M Oncol
Slide 23: One Platform, Many Customized Solutions
One Platform, Many Customized Solutions Meeting customers where they are, powering growth across expanding platforms How we win Operational Commercial ✓ excellence ▣ NPI machine execution Differentiated Silicon Platform Speed and Scale Twist products are for research use only . The products presente
Slide 24: Executing with Increasing Visibility, Delivering Durable Growth
Executing with Increasing Visibility, Delivering Durable Growth Triple Digit % Strong Growth Guided $123 to Order Growth Revenue Growth Trajectory $124M in 4Q FY26 for AI-enabled DD 23% YoY growth for 14th quarter of consecutive growth More than double revenue Growth of approximately 25% Meet or exc
Slide 25: Writing the Future
Writing the Future
Slide 26: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation (In Thousands) FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY2025 GAAP Net Income (Loss) ($139,931) ($152,098) ($217,863) ($204,618) $(208,726) $(77,670) Add (Deduct) Adjustments: Interest income (1,499) (435) (3,062) (14,365) (15,344) (11,364) Interest expense 787 367 80
Slide 27: Adjusted R&D and SG&A Expenses Reconciliation
Adjusted R&D and SG&A Expenses Reconciliation (In Millions) FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 R&D Expenses — GAAP $43.0 $69.1 $120.3 $106.9 $90.9 $80.3 Adjusted to exclude: Depreciation and Amortization 3.0 3.2 3.5 4.0 3.0 1.3 Stock-based Compensation Expense 3.3 10.2 19.5 13.9 11.2 9.
Slide 28: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation (In Thousands) Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 GAAP Net Income ($46,243) ($43,008) ($45,492) ($85,571) ($34,655) ($31,594) ($39,328) $20,390 ($27,138) ($30,507) ($44,021) ($35,051) (Loss) Add (Deduct) Adju
Slide 29: Adjusted R&D and SG&A Expenses Reconciliation
Adjusted R&D and SG&A Expenses Reconciliation (In Millions) Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 R&D Expenses — $23.7 $23.1 $24.1 $22.5 $21.1 $21.3 $23.9 $18.0 $17.0 $17.1 $19.7 $18.0 GAAP Adjusted to exclude: Depreciation and 0.8 0.9 0.9 0.